NCT06690307 Oxycodone Versus Sufentanil in Patient-controlled Intravenous Analgesia After Laparoscopic Hysterectomy
| NCT ID | NCT06690307 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Affiliated Hospital of Nantong University |
| Condition | Laparoscopic Hysterectomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2024-12-03 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 64 participants in total. It began in 2024-12-03 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is designed to evaluate the efficacy and safety of hydrocodone in patient-controlled intravenous analgesia (PCIA) during gynecological laparoscopy, thus to explore suitable PCIA scheme to optimize postoperative pain management for patients undergoing gynecological laparoscopic surgeries.
Eligibility Criteria
Inclusion Criteria: * selective laparoscopic hysterectomy * general anesthesia * ASA classification I - III * aged 18 - 65 years Exclusion Criteria: * allergy to oxycodone or any other drugs will be used in the study * preoperative opioids medication * opioids abuse * hepatic or renal dysfunction * cardiovascular or pulmonary dysfunction * lack of full civil capacity or refuse to participate
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06690307 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 65 Years, studying Laparoscopic Hysterectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06690307 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06690307 currently recruiting?
Yes, NCT06690307 is actively recruiting participants. Contact the research team at tdfylsy@ntu.edu.cn for enrollment information.
Where is the NCT06690307 trial being conducted?
This trial is being conducted at Nantong, China.
Who is sponsoring the NCT06690307 clinical trial?
NCT06690307 is sponsored by Affiliated Hospital of Nantong University. The trial plans to enroll 64 participants.